Conditionally replicative adenovirus for gastrointestinal cancers

Bibliography

• JEMAL A, TIWARI RC, MURRAY T et al: Cancer statistics, 2004. CA Cancerj Clin. (2004) 54:8–29.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-WOLF G, SCHMIDT-WOLF IG: Human cancer and gene therapy. Ann. Hematol (1994) 69:273–279.
   PubMed Web of Science ®Google Scholar
• HERRMANN F: Cancer gene therapy: principles, problems, and perspectives. Mol Med. (1995) 73:157–163.
   Web of Science ®Google Scholar
• CULVER KW, BLAESE RM: Gene therapy for cancer. Trends Genet. (1994) 10:174–178.
   PubMed Web of Science ®Google Scholar
• FREEMAN SM, ZWIEBEL JA: Gene therapy of cancer. Cancer Invest. (1993) 11:676–688.
   PubMed Web of Science ®Google Scholar
• ANDERSON WF: September 14, 1990: thebeginning. Hum. Gene Thec (1990) 1:371–372.
   PubMed Web of Science ®Google Scholar
• ANDERSON WF: Prospects for human gene therapy. Science (1984) 226:401–409.
   PubMed Web of Science ®Google Scholar
• LOSORDO DW, VALE PR, HENDEL RC et al.: Phase 112 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation (2002) 105: 2012-2018.
   Google Scholar
• HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. (2002) 346:1185–1193.
   PubMed Web of Science ®Google Scholar
• HEIDEMAN DA, GERRITSEN WR, CRAANEN ME: Gene therapy for gastrointestinal tract cancer: a review. Scand. Gastroenterol Suppl (2000) 232:93–100.
   PubMedGoogle Scholar
• HAUSES M, SCHACKERT HK: Gene therapy and gastrointestinal cancer: concepts and clinical facts. Langenbecks Arch. Surg. (1999) 384:479–488.
   PubMed Web of Science ®Google Scholar
• BLUM HE: Molecular biology and gene therapy in gastroenterology and hepatology. Eur. Gastroenterol Hepatol (1999) 11:1–7.
   PubMed Web of Science ®Google Scholar
• CHAUHAN SS: Gene therapy-how close to a therapeutic reality. Trop. Gastroenterol (1998) 19:79–81.
   PubMedGoogle Scholar
• PANDHA HS, LEMOINE NR: Gene therapy in gastroenterology. Gut (1996) 38:161–165.
   PubMed Web of Science ®Google Scholar
• CHANG AG, WU GY: Gene therapy: applications to the treatment of gastrointestinal and liver diseases. Gastroenterology (1994) 106:1076–1084.
   PubMed Web of Science ®Google Scholar
• FRIESS H, KLEEFF J, KORC M, BUCHLER MW: Molecular aspects of pancreatic cancer and future perspectives. Dig. Surg. (1999) 16:281–290.
   PubMed Web of Science ®Google Scholar
• ASPINALL RJ, LEMOINE NR: Gene therapy for pancreatic and biliary malignancies. Ann. Oncol. (1999) 10:188–192.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, ABRAMS R, CAMERON J et al.: A Phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum. Gene Then (1998) 9:1951–1971.
   PubMed Web of Science ®Google Scholar
• SEEMAYER TA, CAVENEE WK: Molecular mechanisms of oncogenesis. Lab. Invest. (1989) 60:585–599.
   PubMed Web of Science ®Google Scholar
• ROTH JA, CRISTIANO RJ: Gene therapyfor cancer: what have we done and where are we going?' Nati Cancer Inst. (1997) 89:21–39.
   Google Scholar
• MARSMAN WA, BUSKENS CJ, WESSELING JG et al.: Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo. Gut (2004) 11:289–296.
   Google Scholar
• SCHRUMP DS, CHEN GA, CONSULT U, JINX, ROTH JA: Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Tiler. (1996) 3:357–364.
   Web of Science ®Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS Aet al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science (1996) 274:373–376.
   Google Scholar
• ASADA T: Treatment of human cancer withmumps virus. Cancer (1974) 34:1907–1928.
   PubMed Web of Science ®Google Scholar
• SOUTHAM CM, MOORE AE: Induced virus infection in man by Egypt isolated of West Nile virus. Trop. Med. Hyg. (1954) 3:19–50.
   Web of Science ®Google Scholar
• TELERMAN A, TUYNDER M, DUPRESSOIR T et al.: A model for tumor suppression using H-1 parvovirus. Proc. Natl. Acad. Sci. USA (1993) 90:8702–8706.
   PubMed Web of Science ®Google Scholar
• MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252:854–856.
   PubMed Web of Science ®Google Scholar
• MARKERT JM, MALICK A, COEN DM,MARTUZA RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (1993) 32:597–603.
   PubMed Web of Science ®Google Scholar
• MINETA T, RABKIN SD, MARTUZA RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. (1994) 54:3963–3966.
   PubMed Web of Science ®Google Scholar
• CHAMBERS R, GILLESPIE GY, SOROCEANU L et al.: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA (1995) 92:1411–1415.
   PubMed Web of Science ®Google Scholar
• NORMAN KL, LEE PW: Reovirus as a novel oncolytic agent.' Clin. Invest. (2000) 105:1035–1038.
   Google Scholar
• COFFEY MC, STRONG JE, FORSYTH PA, LEE PW: Reovirus therapy of tumors with activated Ras pathway. Science (1998) 282:1332–1334.
   PubMed Web of Science ®Google Scholar
• GROTE D, RUSSELL SJ, CORNU TI et al.: Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 97:3764–3754.
   Google Scholar
• RUSSELL SJ: RNA viruses as virotherapyagents. Cancer Gene Then (2002) 9:961–966.
   PubMed Web of Science ®Google Scholar
• PECORA AL, RIZVI N, COHEN GI et al.: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.' Clin. Oncol. (2002) 20:2251–2266.
   Google Scholar
• SMITH R, HUEBNER R, ROWE W, SCHATTEN W, THOMAS L: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (1956) 9:1211–1218.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, BALAGUE C, CURIEL DT: Replicative adenoviruses for cancer therapy. Nat. Biotechnol. (2000) 18:723–727.
   PubMed Web of Science ®Google Scholar
• ANDREANSKY SS, HE B, GILLESPIE GY et al.: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Nati Acad. Sci. USA (1996) 93:11313–11318.
   PubMed Web of Science ®Google Scholar
• HALLENBECK PL, CHANG YN, HAY C et al.: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Mei: (1999) 10:1721–1733.
   Google Scholar
• SHENK T: Adenoviridae: the viruses andtheir replication. In: Field's Virology Volume 2. Fields B, Knipe D, Howley P (Eds), Lipponcott-Raven, Philadelphia, USA (1996):2111–2148.
   Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MCCORMICK F, VON HOFF DD, KIRN DH: ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. (1997) 3:639–645.
   PubMed Web of Science ®Google Scholar
• FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al.: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 19:2–12.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ R, SCHUUR ER, LIM HY,HENDERSON GA, SIMONS JW, HENDERSON DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559–2563.
   PubMed Web of Science ®Google Scholar
• HEISE C, LEMMON M, KIRN D: Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. (2000) 6:4908–4914.
   PubMedGoogle Scholar
• GANLY I, KIRN D, ECKHARDT G et al:A Phase I study of Onyx-015, an ElB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. (2000) 6:798–806.
   PubMed Web of Science ®Google Scholar
• MULVIHILL S, WARREN R, VENOOK A et al.: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Mei: (2001) 8:308–315.
   Google Scholar
• HECHT JR, BEDFORD R, ABBRUZZESE JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. (2003) 9:555–561.
   PubMed Web of Science ®Google Scholar
• REID T, GALANIS E, ABBRUZZESE Jet al.: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (d11520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. (2002) 62:6070–6079.
   Google Scholar
• REID T, GALANIS E, ABBRUZZESE J et al.: Intra-arterial administration of a replication-selective adenovirus ($311520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther. (2001) 8:1618–1626.
   PubMed Web of Science ®Google Scholar
• AKIYAMA T: Wnt/beta-catenin signaling. Cytokine Growth Factor Rev (2000) 11:273–282.
   PubMed Web of Science ®Google Scholar
• FUERER C, IGGO R: Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Titer. (2002) 9:270–281.
   Web of Science ®Google Scholar
• LI Y, CHEN Y, DILLEY J et al.: Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, 0V798, for colorectal cancer therapy. MM. Cancer Titer. (2003) 2:1003–1009.
   PubMed Web of Science ®Google Scholar
• WILLIAMS C, SHATTUCK-BRANDT RL, DUBOIS RN: The role of COX-2 in intestinal cancer. Ann. NY Acad. Sci. (1999) 889:72–83.
   PubMed Web of Science ®Google Scholar
• TSUJII M, DUBOIS RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 83:493–501.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, ALEMANY R, ADACHI Y, GRIZZLE WE, CURIEL DT: Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. MM. Ther. (2001) 3:385–394.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, DAVYDOVA J, WANG M et al.: Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 125:1203–1218.
   PubMed Web of Science ®Google Scholar
• ADACHI Y, RAYNOLDS PN, YAMAMOTO M et al.: Midkine promoter-based adenovirus vector gene delivery for pediatric solid tumors. Cancer Res. (2000) 60:4305–4310.
   PubMed Web of Science ®Google Scholar
• WESSELING JG, YAMAMOTO M, ADACHI Y et al.: Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. (2001) 8:990–996.
   PubMed Web of Science ®Google Scholar
• CURIEL DT: Strategies to adapt adenoviralvectors for targeted delivery. Ann. NY Acad. Sci. (1999) 886:158–171.
   PubMed Web of Science ®Google Scholar
• REYNOLDS PN, ZINN KR, GAVRILYUK VD et al.: A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium M vivo. MM. Ther. (2000) 2:562–578.
   PubMed Web of Science ®Google Scholar
• DMITRIEV I, KASHENTSEVA E, ROGERS BE, KRASNYKH V, CURIEL DT: Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Viral. (2000) 74:6875–6884.
   PubMed Web of Science ®Google Scholar
• VAN BEUSECHEM VW, MASTENBROEK DC, VAN DEN DOEL PB et al.: Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther. (2003) 10:1982–1991.
   Google Scholar
• HEMMINKI A, DMITRIEV I, LIU B, DESMOND RA, ALEMANY R, CURIEL DT: Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. (2001) 61:6377–6381.
   PubMed Web of Science ®Google Scholar
• HEMMINKI A, WANG M, HAKKARAINEN T, DESMOND RA, WAHLFORS J, CURIEL DT: Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther. (2003) 10:583–588.
   PubMed Web of Science ®Google Scholar
• KRASNYKH VN, MIKHEEVA GV, DOUGLAS JT, CURIEL DT: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Viral. (1996) 70:6839–6846.
   PubMed Web of Science ®Google Scholar
• WESSELING JG, BOSMA PJ, KRASNYKH V et al.: Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. (2001) 8:969–976.
   PubMed Web of Science ®Google Scholar
• DAVYDOVA J, LE L, GAVROKOVA T, WANG M, KRASNYKH V, YAMAMOTO M: Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma. Cancer Res. (2004) 64:4319–4327.
   PubMed Web of Science ®Google Scholar
• ONO HA, DAVYDOVA J, LE LP et al.:Transcriptional and transductional optimisation of adenoviral vectors for gastric cancer. Ma Ther. (2003) 7:S360–S361.
   Web of Science ®Google Scholar
• CASCALLO M, CAPELLA G, MAZO A, ALEMANY R: Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res. (2003) 63:5544–5550.
   PubMed Web of Science ®Google Scholar
• MEURS E, CHONG K, GALABRU J et al.: Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell (1990) 62:379–390.
   PubMed Web of Science ®Google Scholar
• MUNDSCHAU LJ, FALLER DV: Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J. Biol Chem. (1992) 267:23092–23098.
   PubMed Web of Science ®Google Scholar
• AHMED A, THOMPSON J, EMILIUSEN L et al.: A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol (2003) 21:771–777.
   PubMed Web of Science ®Google Scholar
• WILDNER O, MORRIS JC: The role of the ElB 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res. (2000) 60:4167–4174.
   PubMed Web of Science ®Google Scholar
• LAMBRIGHT ES, AMIN K, WIEWRODT R et al.: Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. (2001) 8:946–953.
   PubMed Web of Science ®Google Scholar
• DORONIN K, 10TH K, KUPPUSWAMY M, KRAJCSI P, TOLLEFSON AE, WOLD WS: Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology (2003) 305:378–387.
   Google Scholar
• SAUTHOFF H, PIPIYA T, HEITNER S et al.: Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum. Gene Ther. (2002) 13:1859–1871.
   PubMed Web of Science ®Google Scholar
• KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. Nat. Med. (2000) 6:879–885.
   PubMed Web of Science ®Google Scholar
• KIRN D: Clinical research results with d11520 (Onyx-015), a replication- selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. (2001) 8:89–98.
   Google Scholar
• LAMFERS ML, GRILL J, DIRVEN CM et al.: Potential of the conditionally replicative adenovirus Ad5-De1ta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. (2002) 62:5736–5742.
   PubMed Web of Science ®Google Scholar
• GEOERGER B, GRILL J, OPOLON P et al.: Potentiation of radiation therapy by the oncolytic adenovirus d11520 (ONYX-015) in human malignant glioma xenografts. Br. J. Cancer (2003) 89:577–584.
   PubMed Web of Science ®Google Scholar
• 10TH K, TARAKANOVA V, DORONIN K et al.: Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther. (2003) 10:193–200.
   Google Scholar
• YANG CT, YOU L, UEMATSU K, YEH CC, MCCORMICK F, JABLONS DM: p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. (2001) 61:5959–5963.
   PubMed Web of Science ®Google Scholar
• EDWARDS SJ, DIX BR, MYERS CJ et al:Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J. Virol (2002) 76:12483–12490.
   PubMed Web of Science ®Google Scholar
• GOMEZ-MANZANO C, BALAGUE C, ALEMANY R et al: A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene (2004) 23: 1821-1828.
   Google Scholar
• BALAGUE C, NOYA F, ALEMANY R, CHOW LT, CURIEL DT: Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. Virol (2001) 75:7602–7611.
   Web of Science ®Google Scholar
• HOWE JA, DEMERS GW, JOHNSON DE et al.: Evaluation of El-mutant adenoviruses as conditionally replicating agents for cancer therapy. Ther. (2000) 2:485–495.
   Google Scholar
• DEWEESE TL, VAN DER POEL H, LI S et al.: A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. (2001) 61:7464–7472.
   Google Scholar
• CHAUDHURI TR, ROGERS BE, BUCHSBAUM DJ, MOUNTZ JM, ZINN KR: A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol (2001) 83:432–438.
   PubMed Web of Science ®Google Scholar
• CHAUDHURI TR, MOUNTZ JM, ROGERS BE, PARTRIDGE EE, ZINN KR: Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. Gynecol Oncol (2001) 82:581–589.
   PubMed Web of Science ®Google Scholar
• PENG KW, TENEYCK CJ, GALANIS E, KALLI KR, HARTMANN LC, RUSSELL SJ: Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. (2002) 62:4656–4662.
   PubMed Web of Science ®Google Scholar
• CLYDE WA JR: Experimental models forstudy of common respiratory viruses. Environ. Health Perspect. (1980) 35:107–112.
   PubMed Web of Science ®Google Scholar
• HAY JG: 'Man's best friend': a new modelsystem for cancer therapeutics? Mol Ther. (2003) 7:144–145.
   Google Scholar
• HEMMINKI A, KANERVA A, KREMER EJ et al.: A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Ma Ther. (2003) 7:163–173.
   PubMed Web of Science ®Google Scholar